Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | TRPM5 | Q9NZQ8 | 15/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458951 | 0.87 | TRPM5 (0.35) | TRPM5SLC6A2SLC6A4SLC6A3TRPA1 | |
| SCHEMBL2461294 | 0.77 | AKT2 (0.43) | PIK3CAMTORTRPM5 | |
| SCHEMBL26260180 | 0.73 | CYP1A2 (0.46) | CHEK1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2462909 | 0.72 | DYRK1A (0.53) | — | |
| SCHEMBL2459132 | 0.72 | ABL1 (0.40) | PIK3CAMTORTRPM5SLC6A2SLC6A4 | |
| SCHEMBL26260213 | 0.72 | ESR1 (0.41) | CHEK1CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL2457682 | 0.71 | NISCH (0.45) | PIK3CAMTORTRPM5TRPA1CYP1A2 | |
| SCHEMBL18608517 | 0.70 | KIF11 (0.43) | PIK3CAMTORTRPM5 | |
| SCHEMBL2457772 | 0.70 | THRB (0.39) | — | |
| SCHEMBL2462312 | 0.69 | CYP11B1 (0.57) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2011-09-29 | — | — | US | disclosed |
| WO-2010068287-A2 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | ANGION BIOMEDICA CORP. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237633-A1 | SMALL MOLECULE MODULATORS OF HEPATOCYTE GROWTH FACTOR (SCATTER FACTOR) ACTIVITY | HGF, HDGF, MET | PIK3CA 3035/4885MTOR 657/4885TRPM5 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.